COMPANY

BioCryst Pharmaceuticals

HQ: Durham, NC source · biocryst.com ↗ · Southeast

FDA-approved therapeutic company Clinical Phase 3

24 open jobs · last seen Oct 23, 2026 · 67 sources

Location: Durham, NC · source · Oct 15, 2026

Profile checked Oct 10, 2026

Keywords: Influenza Hereditary Angioedema HAE Paroxysmal Nocturnal Hemoglobinuria COVID-19 Gout Lymphoma Prophylaxis Seasonal Influenza Cough Sore Throat Nasal Congestion Headache Hyperuricemia Arthritis Joint Disease hepatitis c Netherton Syndrome Diabetic Macular Edema Pediatric PNH HAE Hereditary Angioedema Complement 3 Glomerulopathy Immunoglobulin A Nephropathy Membranous Nephropathy Marburg Virus Disease Yellow Fever Filovirus Infections Ebola Virus Infection Uncomplicated Human Influenza Acute Myalgia Fatigue Fever Renal Insufficiency Leukemia, Lymphocytic, Chronic Chronic Lymphocytic Leukemia Leukemia Cutaneous T-cell Lymphoma

24Open jobs 54Trials (company is sponsor)1FDA records (2 yrs)17NIH grants

Hiring

Title	Location (from posting)	Employer posted	First seen
Senior Search & Evaluation Director	US_North Carolina_Remote	Oct 20, 2026	Oct 21, 2026
Sr. Clinical Data Manager (contract)	US_North Carolina_Remote	Oct 17, 2026	Oct 18, 2026
Regional Business Director	10 locations (listed on the posting)	Oct 15, 2026	Oct 16, 2026
Contracts Manager	2 locations (listed on the posting)	Oct 15, 2026	Oct 16, 2026
Regional Business Director	6 locations (listed on the posting)	Oct 15, 2026	Oct 16, 2026

See all 24 jobs

Trial and FDA signals

Drug approval + hiring FDA approval for ORLADEYO (NDA 219776, Dec 11, 2025); 10 manufacturing/quality or commercial roles open. FDA NDA 219776 (Dec 11, 2025)
Evidence (1 event)
- Dec 11, 2025 · FDA NDA 219776
  openFDA drugsfda: application_number=NDA219776; sponsor_name='BIOCRYST'; submission_type=ORIG; submission_number=1; submission_status=AP; submission_status_date=20251211; submission_class_code=TYPE 3; brand_name=['ORLADEYO']

Job counts as of Oct 18, 2026. All trial and FDA signals

Timeline

Oct 5, 2026 Board tracked Radar started tracking this company’s job board (24 open jobs at last check). source ↗
Dec 11, 2025 FDA FDA Original approval: ORLADEYO (berotralstat dihydrochloride) — NDA219776, Dec 11, 2025. Applicant at approval: BioCryst Pharmaceuticals, Inc. source ↗
Oct 2, 2025 Trial start Phase 1: A Study of Avoralstat In Participants With Diabetic Macular Edema source ↗
Sep 26, 2024 Trial start Phase 1: A Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of BCX17725 source ↗
Oct 24, 2023 Trial start Phase 1: Dose Escalation of BCX10013 in Participants with Paroxysmal Nocturnal Hemoglobinuria (PNH) source ↗
Jan 18, 2023 Trial start Phase 2: Long-term Safety of BCX9930 in Participants With Paroxysmal Nocturnal Hemoglobinuria source ↗
Oct 25, 2022 Trial start Phase 3: Berotralstat Treatment in Children With Hereditary Angioedema source ↗
Feb 18, 2022 Trial start Phase 2: Study to Evaluate the Safety, Tolerability of BCX9930 in Participants With Either Complement 3 Glomerulopathy (C3G), Immunoglobulin A Nephropathy (IgAN), or Primary Membranous Nephropathy (PM source ↗
Dec 6, 2021 Trial start Phase 2: BCX9930 for the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) in Participants With Inadequate Response to C5 Inhibitor Therapy source ↗
Oct 26, 2021 Trial start Phase 2: BCX9930 for the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) in Participants Not Receiving Other Complement Inhibitor Therapy source ↗
Jul 23, 2021 Trial start Phase 3: Open-label Berotralstat Access to HAE Patients Previously Enrolled in Berotralstat Studies source ↗
Dec 18, 2020 Trial start Phase 2: A Long-Term Safety Study of BCX9930 in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) source ↗
Apr 9, 2020 Trial start Phase 1: A Study to Evaluate the Safety, Pharmacokinetics and Antiviral Effects of Galidesivir in Yellow Fever or COVID-19 source ↗
Mar 3, 2020 Trial start Phase 1/Phase 2: First-in-Human Study of BCX9930 in Healthy Volunteers and Patients With PNH source ↗
Dec 27, 2018 Trial start Phase 3: Study to Evaluate the Efficacy and Safety of BCX7353 as an Oral Treatment for the Prevention of HAE Attacks in Japan source ↗
Dec 10, 2018 Trial start Phase 1: A Study to Evaluate the Single Dose Safety, Tolerability and Pharmacokinetics of IV BCX4430 source ↗
Feb 16, 2018 Trial start Phase 2/Phase 3: A Long Term Safety Study of BCX7353 in Hereditary Angioedema source ↗
Feb 6, 2018 Trial start Phase 3: Efficacy and Safety Study of BCX7353 as an Oral Treatment for the Prevention of Attacks in HAE source ↗
Jul 31, 2017 Trial start Phase 2: Study of BCX7353 as a Treatment for Attacks of Hereditary Angioedema source ↗
Feb 27, 2017 Trial start Phase 1: A Relative Bioavailability Study of Two Formulations of BCX7353 source ↗
Feb 17, 2017 Trial start Phase 1: A Drug-Drug Interaction Study to Evaluate Drug Transporter Interactions source ↗
2016-08 Trial start Phase 2: Efficacy and Safety of BCX7353 to Prevent Angioedema Attacks in Subjects With Hereditary Angioedema source ↗
2016-03 Trial start Phase 1: An Open-label Drug-Drug Interaction Study to Evaluate the Effect of BCX7353 on Cytochrome P450 Enzyme Activity Using Probe Substrates source ↗
2015-12 Trial start Phase 3: Safety, PK and Effectiveness of IV Peramivir in Elderly and Higher Risk Subjects With Uncomplicated Influenza source ↗
2015-12 Trial start Phase 3: Open-label, Long-term Safety Study of Avoralstat in Subjects With Hereditary Angioedema source ↗

Showing 25 of 50 dated events.

Upcoming milestones

2026-10 (ESTIMATED) · Phase 1 · A Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of BCX17725 · NCT06539507
2031-08 (ESTIMATED) · Phase 3 · Open-label Berotralstat Access to HAE Patients Previously Enrolled in Berotralstat Studies · NCT04933721

Estimated primary completion per ClinicalTrials.gov. Dates move.

Open jobs 24

Title	Location (from posting, not HQ)	Employer posted	First seen	Level
Senior Search & Evaluation Director	US_North Carolina_Remote	Oct 20, 2026	Oct 21, 2026	Not stated
Sr. Clinical Data Manager (contract)	US_North Carolina_Remote	Oct 17, 2026	Oct 18, 2026	Not stated
Regional Business Director	10 locations (listed on the posting)	Oct 15, 2026	Oct 16, 2026	Not stated
Contracts Manager	2 locations (listed on the posting)	Oct 15, 2026	Oct 16, 2026	Not stated
Regional Business Director	6 locations (listed on the posting)	Oct 15, 2026	Oct 16, 2026	Not stated
Sr. Clinical Data Manager	US_North Carolina_Remote	Oct 15, 2026	Oct 16, 2026	Not stated
Product Safety Associate - Postmarketing (Contract)	US_North Carolina_Remote	Oct 15, 2026	Oct 16, 2026	Not stated
Rare Disease Specialist (営業担当) - 日本	APAC_Japan	Oct 13, 2026	Oct 5, 2026	Mid
Bilingual Patient Support Manager - Philadelphia/New Jersey	3 locations (listed on the posting)	Oct 5, 2026	Oct 5, 2026	Mid
Exec. Director, Biostatistics	2 locations (listed on the posting)	Oct 2, 2026	Oct 5, 2026	Executive
Corporate Communications Content Manager	3 locations (listed on the posting)	Oct 2, 2026	Oct 5, 2026	Mid
VP, Drug Substance	2 locations (listed on the posting)	Oct 1, 2026	Oct 5, 2026	Executive
Assoc. Director, IT Business Partner - Pharmaceutical Development	3 locations (listed on the posting)	Oct 1, 2026	Oct 5, 2026	Senior
Assoc. Director, Regulatory Affairs Strategy	US_North Carolina_Remote	Sep 28, 2026	Oct 5, 2026	Senior
VP, Biostatistics	2 locations (listed on the posting)	Sep 28, 2026	Oct 5, 2026	Executive
Exec. Director, Statistical Programming	US_North Carolina_Remote	Sep 25, 2026	Oct 5, 2026	Executive
Assoc. Director, Analytical Development	US_North Carolina_Remote	Sep 23, 2026	Oct 5, 2026	Senior
Director, Clinical Development Sciences	US_North Carolina_Remote	Sep 23, 2026	Oct 5, 2026	Senior
Sales - Rare Disease Specialist (Los Angeles)	2 locations (listed on the posting)	Sep 23, 2026	Oct 5, 2026	Mid
VP, Global Clinical Development	US_North Carolina_Remote	Sep 23, 2026	Oct 5, 2026	Executive
Sales - Rare Disease Specialist (Hudson Valley, NY)	3 locations (listed on the posting)	Sep 23, 2026	Oct 5, 2026	Mid
Exec. Director, US Market Access	2 locations (listed on the posting)	Sep 23, 2026	Oct 5, 2026	Executive
Sr. Systems Engineer (Onsite Support)	2 locations (listed on the posting)	Sep 23, 2026	Oct 5, 2026	Senior
Director, Drug Product Development	US_North Carolina_Remote	Sep 23, 2026	Oct 5, 2026	Senior

Level (Entry/Mid/Senior/Executive) is estimated from the job title and required years of experience. Descriptions are short excerpts (about the first 60 words) of the posting plus skills picked out of it; use Read full posting for the complete text.

Clinical trials (lead sponsor) Showing 50 of 54

Record	Title	Phase	Status	Start	Primary completion
NCT06539507	A Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of BCX17725	Phase 1	Recruiting	Sep 26, 2024	2026-10 (estimated)
NCT01224795	A Study to Evaluate the Efficacy and Safety of Intravenous Peramivir in Subjects With Uncomplicated Influenza.	Phase 3	Withdrawn	2010-10	2010-11 (actual)
NCT00486980	Intramuscular Peramivir for the Treatment of Uncomplicated Influenza	Phase 3	Withdrawn	Not listed	Not listed
NCT07228559	A Study of Avoralstat In Participants With Diabetic Macular Edema	Phase 1	Terminated	Oct 2, 2025	Apr 17, 2026 (actual)
NCT05453968	Berotralstat Treatment in Children With Hereditary Angioedema	Phase 3	Active, not recruiting	Oct 25, 2022	Sep 11, 2024 (actual)
NCT04933721	Open-label Berotralstat Access to HAE Patients Previously Enrolled in Berotralstat Studies	Phase 3	Enrolling by invitation	Jul 23, 2021	2031-08 (estimated)
NCT02303626	12-Week Safety and Efficacy Study of BCX4161 as an Oral Prophylaxis Against HAE Attacks	Phase 2/Phase 3	Completed	Dec 17, 2014	2016-01 (actual)
NCT05741346	Long-term Safety of BCX9930 in Participants With Paroxysmal Nocturnal Hemoglobinuria	Phase 2	Terminated	Jan 18, 2023	Jan 31, 2025 (actual)
NCT04702568	A Long-Term Safety Study of BCX9930 in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)	Phase 2	Terminated	Dec 18, 2020	Oct 4, 2023 (actual)
NCT05116774	BCX9930 for the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) in Participants With Inadequate Response to C5 Inhibitor Therapy	Phase 2	Terminated	Dec 6, 2021	Sep 14, 2023 (actual)
NCT06100900	Dose Escalation of BCX10013 in Participants with Paroxysmal Nocturnal Hemoglobinuria (PNH)	Phase 1	Completed	Oct 24, 2023	Dec 11, 2024 (actual)
NCT05116787	BCX9930 for the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) in Participants Not Receiving Other Complement Inhibitor Therapy	Phase 2	Terminated	Oct 26, 2021	Sep 18, 2023 (actual)
NCT03873116	Study to Evaluate the Efficacy and Safety of BCX7353 as an Oral Treatment for the Prevention of HAE Attacks in Japan	Phase 3	Completed	Dec 27, 2018	Jul 8, 2021 (actual)
NCT05162066	Study to Evaluate the Safety, Tolerability of BCX9930 in Participants With Either Complement 3 Glomerulopathy (C3G), Immunoglobulin A Nephropathy (IgAN), or Primary Membranous Nephropathy (PMN)	Phase 2	Terminated	Feb 18, 2022	Sep 23, 2022 (actual)
NCT03485911	Efficacy and Safety Study of BCX7353 as an Oral Treatment for the Prevention of Attacks in HAE	Phase 3	Completed	Feb 6, 2018	Apr 10, 2019 (actual)
NCT03472040	A Long Term Safety Study of BCX7353 in Hereditary Angioedema	Phase 2/Phase 3	Completed	Feb 16, 2018	Apr 27, 2022 (actual)
NCT04330534	First-in-Human Study of BCX9930 in Healthy Volunteers and Patients With PNH	Phase 1/Phase 2	Completed	Mar 3, 2020	Nov 11, 2020 (actual)
NCT03800173	A Study to Evaluate the Single Dose Safety, Tolerability and Pharmacokinetics of IV BCX4430	Phase 1	Completed	Dec 10, 2018	Apr 30, 2019 (actual)
NCT03891420	A Study to Evaluate the Safety, Pharmacokinetics and Antiviral Effects of Galidesivir in Yellow Fever or COVID-19	Phase 1	Terminated	Apr 9, 2020	Jan 31, 2021 (actual)
NCT03240133	Study of BCX7353 as a Treatment for Attacks of Hereditary Angioedema	Phase 2	Completed	Jul 31, 2017	Jan 29, 2019 (actual)
NCT02635724	Safety, PK and Effectiveness of IV Peramivir in Elderly and Higher Risk Subjects With Uncomplicated Influenza	Phase 3	Completed	2015-12	2018-04 (actual)
NCT02870972	Efficacy and Safety of BCX7353 to Prevent Angioedema Attacks in Subjects With Hereditary Angioedema	Phase 2	Completed	2016-08	2017-08 (actual)
NCT02369159	Safety, PK and Effectiveness of IV Peramivir Versus Oseltamivir in Pediatric Subjects With Uncomplicated Influenza	Phase 3	Completed	Mar 11, 2015	Oct 28, 2019 (actual)
NCT00610935	Intramuscular Peramivir in Subjects With Uncomplicated Acute Influenza	Phase 3	Terminated	2008-01	2008-02 (actual)
NCT04428632	Oral Berotralstat Expanded Access Program	Not listed	Approved for marketing	Not listed	Not listed
NCT03202784	A Relative Bioavailability Study of Two Formulations of BCX7353	Phase 1	Completed	Feb 27, 2017	Aug 1, 2017 (actual)
NCT03136237	A Drug-Drug Interaction Study to Evaluate Drug Transporter Interactions	Phase 1	Completed	Feb 17, 2017	Aug 15, 2017 (actual)
NCT02819102	An Open-label Drug-Drug Interaction Study to Evaluate the Effect of BCX7353 on Cytochrome P450 Enzyme Activity Using Probe Substrates	Phase 1	Completed	2016-03	2016-06 (actual)
NCT02319772	A Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BCX4430	1	Completed	2014-12	2016-03 (actual)
NCT02670720	Open-label, Long-term Safety Study of Avoralstat in Subjects With Hereditary Angioedema	Phase 3	Terminated	2015-12	2016-02 (actual)
NCT02448264	First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BCX7353 in Healthy Western and Japanese Volunteers	Phase 1	Completed	2015-05	2015-11 (actual)
NCT00705406	A Phase II, Multicenter, Randomized, Placebo -Controlled, Study To Evaluate The Efficacy and Safety Of Intramuscular Peramivir 600 mg In Subjects With Uncomplicated Acute Influenza	II	Completed	2008-07	2009-04 (actual)
NCT00453999	Evaluation of Efficacy and Safety of Peramivir in Adults With Acute Serious or Potentially Life-threatening Influenza	Phase 2	Completed	2007-07	2008-09 (actual)
NCT00957996	Safety Study of IV Peramivir in Hospitalized Subjects With Confirmed or Suspected Influenza	Phase 3	Completed	2009-10	2010-10 (actual)
NCT00958776	A Study to Evaluate the Efficacy and Safety of IV Peramivir in Addition to Standard of Care Compared to Standard of Care Alone in Adults and Adolescents Who Are Hospitalized Due to Influenza	Phase 3	Terminated	2009-11	2012-11 (actual)
NCT00419263	Evaluation of the Efficacy and Safety of Peramivir in Subjects With Uncomplicated Acute Influenza.	Phase 2	Completed	2007-01	2007-09 (actual)
NCT02218294	Study to Determine How BCX4161 is Metabolized and Eliminated by the Body	Phase 1	Completed	2014-08	2014-09 (actual)
NCT01984788	Safety and Efficacy of Oral BCX4161 as a Prophylactic Treatment for HAE	Phase 2	Completed	2013-11	2014-05 (actual)
NCT02125162	A Study of the Relative Bioavailability of a New Formulation of BCX4161 and the Effect of Food on BCX4161	Phase 1	Completed	2014-04	2014-07 (actual)
NCT01265264	Study to Evaluate sUA Lowering Activity, Safety and Efficacy of Oral Ulodesine Added to Allopurinol	Phase 2	Completed	2010-12	2012-07 (actual)
NCT01407874	A Randomized, Double-Blind, Dose-Response Study of the Safety and Uric Acid Effects of Oral Ulodesine Added to Allopurinol in Subjects With Gout and Concomitant Moderate Renal Insufficiency	Phase 2	Completed	2011-09	2012-07 (actual)
NCT00098332	Forodesine (BCX-1777) in Treating Patients With Refractory Stage IIA, Stage IIB, Stage III, Stage IVA, or Stage IVB Cutaneous T-Cell Lymphoma	Phase 1	Completed	2004-11	2010-12 (actual)
NCT00061880	BCX-1777 in Treating Patients With Refractory Cutaneous T-Cell Lymphoma	Phase 1/Phase 2	Completed	2003-02	2005-01 (actual)
NCT00073944	BCX-1777 in Treating Patients With Refractory Cancer	Phase 1	Completed	2003-04	2005-01 (actual)
NCT00289549	Study of Forodesine Hydrochloride in Patients With Advanced, Fludarabine-refractory Chronic Lymphocytic Leukemia (CLL)	Phase 2	Completed	2005-06	2009-01 (actual)
NCT00985127	Study to Evaluate the Urate-Lowering Activity and Safety of Oral BCX4208 Administered in Subjects With Gout	Phase 2	Completed	2009-09	2010-09 (actual)
NCT00640523	Phase II Study of Forodesine in Subjects With Chronic Lymphocytic Leukemia (CLL)	II	Completed	2008-03	2010-11 (actual)
NCT01129648	Study to Evaluate sUA-Lowering Activity, Safety & PK Interaction of Oral BCX4208 & Allopurinol Admin. in Subjects w/Gout	Phase 2	Completed	2010-05	2010-11 (actual)
NCT00419081	Study of Forodesine Hydrochloride in Patients With Relapsed/Refractory Precursor T-Lymphoblastic Leukemia/Lymphoma Who Have Failed Two or More Prior Treatment Regimens	Phase 2	Terminated	2006-07	2007-03 (actual)
NCT00501735	Forodesine in the Treatment of Cutaneous T-Cell Lymphoma	Phase 2	Completed	2007-07	2010-07 (actual)

FDA records (last 2 years)

Dec 11, 2025 FDA Original approval: ORLADEYO (berotralstat dihydrochloride) — NDA219776, Dec 11, 2025. Applicant at approval: BioCryst Pharmaceuticals, Inc. source ↗

NIH awards 17

Annual award amounts. Total $49.0M.

2023 NIH contract (government contract; not a grant and not an investment round) 272201300017C-P00026-9999-1 FY2023: $440,828 awarded for that fiscal year; activity N01 (OTHER_NIH); PI TAYLOR, RAYMOND; recipient as written: BIOCRYST PHARMACEUTICALS, INC., DURHAM, N source ↗
2021 NIH contract (government contract; not a grant and not an investment round) 272201300017C-P00025-9999-1 FY2021: $1,383,666 awarded for that fiscal year; activity N01 (OTHER_NIH); PI TAYLOR, RAYMOND; recipient as written: BIOCRYST PHARMACEUTICALS, INC., DURHAM, source ↗
2020 NIH contract (government contract; not a grant and not an investment round) 75N93020C00055-0-9999-1 FY2020: $6,326,480 awarded for that fiscal year; activity N01 (OTHER_NIH); PI SHERIDAN, WILLIAM; recipient as written: BIOCRYST PHARMACEUTICALS, INC., DURHAM, N source ↗
2020 NIH contract (government contract; not a grant and not an investment round) 272201300017C-P00023-9999-1 FY2020: $2,896,627 awarded for that fiscal year; activity N01 (OTHER_NIH); PI TAYLOR, RAYMOND; recipient as written: BIOCRYST PHARMACEUTICALS, INC., DURHAM, source ↗
2018 NIH contract (government contract; not a grant and not an investment round) 272201300017C-22-0-1 FY2018: $3,557,707 awarded for that fiscal year; activity N01 (OTHER_NIH); PI TAYLOR, RAYMOND; recipient as written: BIOCRYST PHARMACEUTICALS, INC., DURHAM, NC. De source ↗
2016 NIH contract (government contract; not a grant and not an investment round) 272201300017C-18-0-1 FY2016: $9,601,843 awarded for that fiscal year; activity N01 (OTHER_NIH); PI TAYLOR, RAYMOND; recipient as written: BIOCRYST PHARMACEUTICALS, INC., DURHAM, NC. De source ↗
2015 NIH contract (government contract; not a grant and not an investment round) 272201300017C-9-0-1 FY2015: $3,539,289 awarded for that fiscal year; activity N01 (OTHER_NIH); PI TAYLOR, RAYMOND; recipient as written: BIOCRYST PHARMACEUTICALS, INC., DURHAM, NC. Dev source ↗
2014 NIH contract (government contract; not a grant and not an investment round) 272201300017C-2-0-1 FY2014: $14,916,023 awarded for that fiscal year; activity N01 (OTHER_NIH); PI TAYLOR, RAYMOND; recipient as written: BIOCRYST PHARMACEUTICALS, INC., DURHAM, NC. De source ↗
2013 NIH contract (government contract; not a grant and not an investment round) 272201300017C-0-0-1 FY2013: $4,996,104 awarded for that fiscal year; activity N01 (OTHER_NIH); PI TAYLOR, RAYMOND; recipient as written: BIOCRYST PHARMACEUTICALS, INC., DURHAM, NC. Dev source ↗
Aug 20, 2004 NIH award 5R43AI056877-02 FY2004: $300,000 awarded for that fiscal year; activity R43 (SBIR); PI BABU, Y SUDHAKARA; recipient as written: BIOCRYST PHARMACEUTICALS, INC., BIRMINGHAM, AL. Optimizing Hepatitis C virus N source ↗
Apr 19, 2004 NIH award 1R43HL076929-01 FY2004: $97,990 awarded for that fiscal year; activity R43 (SBIR); PI ARNOLD, CHRISTOPHER S; recipient as written: BIOCRYST PHARMACEUTICALS, INC., BIRMINGHAM, AL. EFFECTS OF TF/FVIIa INHIBIT source ↗
Jul 5, 2003 NIH award 1R43AI056877-01 FY2003: $300,000 awarded for that fiscal year; activity R43 (SBIR); PI BABU, Y SUDHAKARA; recipient as written: BIOCRYST PHARMACEUTICALS, INC., BIRMINGHAM, AL. Optimizing Hepatitis C virus N source ↗
Apr 3, 1995 NIH award 5R44AR041095-03 FY1995: $250,000 awarded for that fiscal year; activity R44 (SBIR); PI BABU, Y SUDHAKARA; recipient as written: BIOCRYST PHARMACEUTICALS, INC., BIRMINGHAM, AL. DESIGN OF INHIBITORS FOR COMPL source ↗
Feb 15, 1994 NIH award 2R44AR041095-02 FY1994: $250,000 awarded for that fiscal year; activity R44 (SBIR); PI BABU, Y SUDHAKARA; recipient as written: BIOCRYST PHARMACEUTICALS, INC., BIRMINGHAM, AL. DESIGN OF INHIBITORS FOR COMPL source ↗
Sep 30, 1992 NIH award 1R43DK044789-01A1 FY1992: $50,000 awarded for that fiscal year; activity R43 (SBIR); PI BORHANI, DAVID W; recipient as written: BIOCRYST PHARMACEUTICALS, INC., BIRMINGHAM, AL. STRUCTURE-BASED ALDOSE REDUCTA source ↗
Feb 7, 1992 NIH award 1R43AR041095-01 FY1992: $50,000 awarded for that fiscal year; activity R43 (SBIR); PI BABU, Y SUDHAKARA; recipient as written: BIOCRYST PHARMACEUTICALS, INC., BIRMINGHAM, AL. STRUCT.-BASED DESIGN OF INHIB. source ↗
Aug 31, 1991 NIH award 1R43AI031708-01 FY1991: $50,000 awarded for that fiscal year; activity R43 (SBIR); PI BABU, Y SUDHAKARA; recipient as written: BIOCRYST PHARMACEUTICALS, INC., BIRMINGHAM, AL. STRUCT-BASED DESIGN OF INHIBITO source ↗

Connect

See your connections at BioCryst Pharmaceuticals on LinkedIn (search by name, results not checked)

LinkedIn shows your 1st and 2nd-degree connections here from your own login, including who could introduce you. Radar doesn't see your connections.

LinkedIn page linked from the company's own site: source · seen 2026-10-12

Careers page (Oct 8, 2026)